GLP-1 Market
LLY $1188.72 ▲ +2.7% NVO $38.26 ▲ +1.9% PFE $28.00 ▲ +1.8% VKTX $28.54 ▲ +0.6% KLRA $10.53 ▼ -2.8% GPCR $26.68 ▼ -2.9% RHHBY $53.97 ▲ +2.7%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Naronapride

Company
Dr. Falk Pharma GmbH
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Oct 8, 2026

Trial details
  • Terminated NCT NCT00501241

    Phase II, Randomized, Placebo-Controlled Study of ATI-7505 in Patients With Chronic Idiopathic Constipation

    Not yet reported Procter and Gamble 214 participants Est. completion 2008-07 23 sites
    Other conditions: Chronic Constipation
    View official trial listing →
  • Terminated NCT NCT00630370

    A Dose-Ranging Study of ATI 7505 in Patients With Postprandial Distress Syndrome

    Not yet reported Procter and Gamble 6 participants Est. completion 2008-07 64 sites
    Other conditions: Post Prandial Distress Syndrome
    View official trial listing →
  • Completed NCT NCT01094821

    Effect of ATI-7505 on Gastrointestinal Transit in Healthy Volunteers

    Not yet reported, Not yet reported Mayo Clinic 48 participants Est. completion 2005-12 1 site
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT05621811

    Different Doses of Naronapride vs. Placebo in Gastroparesis

    Not yet reported Dr. Falk Pharma GmbH 328 participants Est. completion 2025-09-04 24 sites Stand-alone
    Other conditions: Gastroparesis
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.